NCT00511303View on ClinicalTrials.gov

Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 31, 2000

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

STI571

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

University of Bologna

OTHER